番茄社区

Standard of care prevails in single-center trial

Benefit shown in trial of patients flagged for high risk of cardiotoxicity

Recent developments of interest in cardiovascular medicine

Intranasal bumetanide demonstrated safety, bioequivalence with its oral and IV counterparts

No excess infections when pacemakers were cleaned and repackaged for resource-deprived patients

Most are eligible for weight management indication

Is this the final finding from ORAL Surveillance? Don't count on it.

Procedure also noninferior to anticoagulation for death, stroke, or systemic embolism composite

Drug discontinuations may have leveled any benefit in CLEAR OASIS 9 trial

Japanese trial supports use but event risk might be low enough to suggest a different strategy

Microemboli now questioned as driver of cognitive impairment in atrial fibrillation

One-time treatment with nexiguran ziclumeran tied to decline in serum TTR levels in phase I trial

SUMMIT trial able to show clinical benefit beyond quality-of-life improvement

Jury is still out, however, without more rigorous evidence